Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Valérie Boige, Antoine Hollebecque, David Malka

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.

Original languageEnglish
Pages (from-to)114-128
Number of pages15
JournalSeminars in Oncology
Volume44
Issue number2
DOIs
StatePublished - Apr 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

Keywords

  • Angiogenesis inhibitors
  • Colorectal cancer
  • Pooled analysis
  • Second-line chemotherapy
  • Systematic review

Fingerprint

Dive into the research topics of 'Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis'. Together they form a unique fingerprint.

Cite this